Guardant Health, Inc.

Nasdaq GH · Palo Alto, CA

Works in Dermatology · GI & liver · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health

Guardant Health, Inc. is a clinical trial sponsor based in Palo Alto, CA, listed as Nasdaq GH. It has 6 active clinical trials with 62,947 planned participants, across 7 therapeutic areas. Since 2021 it has completed 2 trials and stopped 0 early.

Trial track record · since 2021

6Active trials62,947 planned participants
2Completed0 with results posted
0Stopped earlyterminated, withdrawn or suspended

Financials · Nasdaq GH

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 6 active trials

StageTrialStatus

Questions about Guardant Health, Inc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-14.

Approve Suite is not affiliated with Guardant Health, Inc..

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.